NME "Approvables" Outnumber Approvals Six To Two In October
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An "approvable" action was three times more likely than approval for the new molecular entities with user fee goals in October, according to an analysis by Pharmaceutical Approvals Monthly.You may also be interested in...
Approvals In Brief
Ranexa Could Be First Approval For First-Line Angina With MERLIN Trial
Novo Nordisk Levemir gets CPMP okay
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: